

(51) International Patent Classification:
C07K 14/705 (2006.01) A61K 38/17 (2006.01)(21) International Application Number:
PCT/US2016/059838(22) International Filing Date:
1 November 2016 (01.11.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/249,836 2 November 2015 (02.11.2015) US
62/373,654 11 August 2016 (11.08.2016) US(71) Applicant: FIVE PRIME THERAPEUTICS, INC.
[US/US]; Two Corporate Drive, South San Francisco,
California 94080 (US).(72) Inventors: BRENNAN, Thomas; Two Corporate Drive,
South San Francisco, California 94080 (US). BELLOVIN,
David; Two Corporate Drive, South San Francisco, Cali-
fornia 94080 (US). BUSH, David; Two Corporate Drive,
South San Francisco, California 94080 (US). SENNINO,Barbara; Two Corporate Drive, South San Francisco,
California 94080 (US).(74) Agents: DOHERTY, Elizabeth A. et al.; McNeill Baur
PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge,
Massachusetts 02140 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT


(57) Abstract: This application relates to CD80 (B7-1) ex-
tracellular domain (ECD) polypeptides and CD80-ECD fu-
sion molecules and their use in treatment of cancer, both
alone and in combination with other therapeutic agents, such
as immune stimulating agents such as PD-1/PD-L1 inhibi-
tors.

Fig. 1A



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

Published:

- with international search report (Art. 21(3))